Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Context: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, affecting approximately 5% to 20% of women of reproductive age. The economic burden of PCOS was previously estimated at approximately $3.7 billion annually in 2020 USD when considering only the costs of the initial diagnosis and of reproductive endocrine morbidities, without considering the costs of pregnancy-related and long-term morbidities. Objective: This study aimed to estimate the excess prevalence and economic burden of pregnancy-related and long-term health morbidities attributable to PCOS. Methods: PubMed, EmBase, and Cochrane Library were searched, and studies were selected in which the diagnosis of PCOS was consistent with the Rotterdam, National Institutes of Health, or Androgen Excess and PCOS Society criteria, or that used electronic medical record diagnosis codes, or diagnosis based on histopathologic sampling. Studies that included an outcome of interest and a control group of non-PCOS patients who were matched or controlled for body mass index were included. Two investigators working independently extracted data on study characteristics and outcomes. Data were pooled using random effects meta-analysis. The I2 statistic was used to assess inter-study heterogeneity. The quality of selected studies was assessed using the Newcastle-Ottawa Scale. Results: The additional total healthcare-related economic burden of PCOS due to pregnancy-related and long-term morbidities in the United States is estimated to be $4.3 billion annually in 2020 USD. Conclusion: Together with our prior analysis, the economic burden of PCOS is estimated at $8 billion annually in 2020 USD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [62]
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [62]
In the citing paper
“The diagnosis of PCOS included the ICD-9 and ICD-10 codes, and these have been validated and used in previous epidemiologic studies.6,10,17,27,32,55, 56, 57”
From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [27]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Self-citationAzziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationWild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970
Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
Azziz, R. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002698 · Cited by 573 · cited 1×
“These criteria, commonly referred to as the Rotterdam criteria, require that two of the following three features to be present for the diagnosis: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, (3) polycystic ovarian morphology on ultrasound, after the exclusion of other etiologie…”
BackgroundSelf-citation
Research works printed but not linked: 5
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 337
- Rohde, 2012, Health Care Expenditures for Uncomplicated Pregnancies, 2009
- Martin, 2019, Births: final data for 2018, Natl Vital Stat Rep., 68, 1
- American College of Obstetricians, Task Force on Hypertension in Pregnancy, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstetrics and Gynecology, 1122
- Pourat, 2013, Costs of Gestational Hypertensive Disorders in California: Hypertension, Preeclampsia, and Eclampsia
Cited by
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M., Patil, M., Rees, D. A., Berry, L., Cree, M. G., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00717-8 · Cited by 306
Self-citationCurrent Guidelines for Diagnosing PCOS
Christ, J. P., & Cedars, M. I. (2023) · Diagnostics · doi:10.3390/diagnostics13061113 · Cited by 340
“Despite causing over USD 8 billion in healthcare costs in the United States, accurate US population-based estimates of incidence and prevalence are lacking and as many as 75% of patients with PCOS are unidentified in clinical practice [2].”
BackgroundPolycystic ovary syndrome as a metabolic disease
Helvaci, N., & Yildiz, B. O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01057-w · Cited by 188
“Women with PCOS are exposed to these metabolic alterations starting from a young age, imposing a high burden on their long-term health and causing a substantial increase in health-care-related costs 4 .”
Adipose Tissue Dysfunction in Polycystic Ovary Syndrome
Bril, F., Ezeh, U., Amiri, M., Hatoum, S., Pace, L., Chen, Y.-H., Bertrand, F., Gower, B., & Azziz, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad356 · Cited by 123
Self-citationBarrera, F. J., Brown, E. D. L., Rojo, A., Obeso, J., Plata, H., Lincango, E. P., Terry, N., Rodríguez-Gutiérrez, R., Hall, J. E., & Shekhar, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106625 · Cited by 91
“Its public health burden is immense, with nearly eight billion US dollars spent in 2020 to manage PCOS-related symptoms among women in the United States alone (10).”
BackgroundPredicting polycystic ovary syndrome with machine learning algorithms from electronic health records
Zad, Z., Jiang, V. S., Wolf, A. T., Wang, T., Cheng, J. J., Paschalidis, I. C., & Mahalingaiah, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1298628 · Cited by 97
Yadav, S., Delau, O., Bonner, A. J., Markovic, D., Patterson, W., Ottey, S., Buyalos, R. P., & Azziz, R. (2023) · eLife · doi:10.7554/elife.85338 · Cited by 85
Self-citationLiu, D., Gao, X., Pan, X., Zhou, T., Zhu, C., Li, F., Fan, J., Targher, G., & Zhao, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02775-0 · Cited by 91
“The annual burden of PCOS and the direct medical costs of NAFLD and related complications were nearly $8 billion and over $137 billion, respectively, in the USA and Europe [11, 12].”
BackgroundInfluentialYu, O., Christ, J. P., Schulze‐Rath, R., Covey, J., Kelley, A., Grafton, J. R., Cronkite, D., Holden, E., Hilpert, J., Sacher, F., et al. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.04.010 · Cited by 100
Chang, K.-J., Chen, J.-H., & Chen, K.-H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169037 · Cited by 108
“According to an article published by Carrie Riestenberg et al. in 2021, it is estimated that PCOS brought about an economic burden of USD 8 billion in 2020, with approximately USD 3.7 billion contributing to an initial diagnosis or management of associated reproductive endocrine disorders [18].”
InfluentialZhang, J., Zhu, Y., Wang, J., Hu, H., Jin, Y., Mao, X., Zhang, H., Yang, Y., Xin, X., & Li, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306991 · Cited by 80
Questioning PCOS phenotypes for reclassification and tailored therapy
Myers, S. H., Russo, M., Dinicola, S., Forte, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.005 · Cited by 74
Data-driven subtypes of polycystic ovary syndrome and their association with clinical outcomes
Gao, X., Zhao, S., Du, Y., Yang, Z., Tian, Y., Zhao, J., Yuan, X., dos Santos, B. R., Wei, D., Cui, L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03984-1 · Cited by 80
“The lack of agreement on clinical subtypes, specifically because of an absence of robust evidence for distinctive subtypes, exacerbates healthcare costs for PCOS subjects, estimated to reach US$8 billion annually in the USA alone 9 .”
Sydora, B. C., Wilke, M. S., McPherson, M., Chambers, S., Ghosh, M., & Vine, D. F. (2023) · BMC Women's Health · doi:10.1186/s12905-023-02732-2 · Cited by 60
“” ◦ “Always do your own research and get more than one opinion on things if you still feel unsure” ask for referral 20 [14.7] ◦ “If you don’t feel heard ask for a new referral, try a naturopath osteopath or even acupuncture it won’t damage and it might help.”
BackgroundInfluentialSingle-cell profiling of the human endometrium in polycystic ovary syndrome
Eriksson, G., Li, C., Sparovec, T. G., Dekanski, A., Torstensson, S., Risal, S., Ohlsson, C., Hirschberg, A. L., Petropoulos, S., Deng, Q., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03592-z · Cited by 65
Epigenetic/circadian clocks and PCOS
Vatier, C., & Christin‐Maître, S. (2024) · Human Reproduction · doi:10.1093/humrep/deae066 · Cited by 65
Optimized Machine Learning for the Early Detection of Polycystic Ovary Syndrome in Women
Panjwani, B., Yadav, J., Mohan, V., Agarwal, N., & Agarwal, S. (2025) · Sensors · doi:10.3390/s25041166 · Cited by 77
“The socio-economic burden in the management of PCOS-related symptoms and morbidity is in the billions of USD annually [19].”
Vine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
“27 110-114 Our results are consistent with these fi ndings and support the concept that type 1 diabetes may predispose individuals to the development of PCOS.”
BackgroundResultDifferentiating Polycystic Ovary Syndrome from Adrenal Disorders
Yeşiladalı, M., Yazici, M. G. K., Attar, E., & Keleştimur, F. (2022) · Diagnostics · doi:10.3390/diagnostics12092045 · Cited by 68
“Polycystic ovary syndrome (PCOS) is an androgen excess disorder that is seen in 5–20% of reproductive age women and represents the most common endocrine problem in this patient population [1,2].”
BackgroundPCOS stratification for precision diagnostics and treatment
Joshi, A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1358755 · Cited by 74
Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis
Neven, A. C. H., Forslund, M., Ranasinha, S., Sethi, P., Dhungana, R. R., Mousa, A., Tay, C. T., Teede, H. J., & Boyle, J. (2026) · Human Reproduction Update · doi:10.1093/humupd/dmaf030 · Cited by 92
Prevalence and Etiology of Eating Disorders in Polycystic Ovary Syndrome: A Scoping Review
Lalonde-Bester, S., Malik, M., Masoumi, R., Ng, K., Sidhu, S., Ghosh, M., & Vine, D. F. (2024) · Advances in Nutrition · doi:10.1016/j.advnut.2024.100193 · Cited by 63
Qu, R., Wang, J., Li, X., Zhang, Y., Yin, T., & Yang, P. (2024) · Toxics · doi:10.3390/toxics12090678 · Cited by 55
“Globally, PCOS affects approximately 15% of women, imposing a significant economic burden [74].”
BackgroundWang, R., Gu, Z., Wang, Y., Yin, X., Liu, W., Chen, W., Huang, Y., Wu, J., Yang, S., Feng, L., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206670 · Cited by 47
Amiri, M., Hatoum, S., Buyalos, R. P., Sheidaei, A., & Azziz, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae917 · Cited by 54
Self-citationIsmayilova, M., & Yaya, S. (2023) · International Health · doi:10.1093/inthealth/ihac028 · Cited by 38
Chen, T., Yu, Y., Jia, F., Luan, P., & Liu, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.960965 · Cited by 37
“7 billion dollars (11), and this figure will be much higher if combined with insulin resistance and other longterm complications (12).”
BackgroundSilva, M. S. B., Decoster, L., Delpouve, G., Lhomme, T., Ternier, G., Prévot, V., & Giacobini, P. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104850 · Cited by 41
Teede, H. J., Moran, L., Morman, R., Gibson‐Helm, M. E., Dokras, A., Berry, L., Laven, J. S. E., Joham, A. E., Piltonen, T., Costello, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103287 · Cited by 49
“1,2,5 10 Despite the prevalence and signi fi cant health and economic burden, 11,12 up to 70% of affected individuals remain undiagnosed.”
Machine learning classification of polycystic ovary syndrome based on radial pulse wave analysis
Lim, J., Li, J., Feng, X., Feng, L., Xia, Y.-M., Xiao, X., Wang, Y., & Xu, Z. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04249-5 · Cited by 42
“The economic burden of PCOS is estimated at USD 8 billion annually [5].”
BackgroundEffects of Ketogenic Diet on Reproductive Hormones in Women With Polycystic Ovary Syndrome
Khalid, K., Apparow, S., Mushaddik, I. L., Anuar, A., Rizvi, S. A. A., & Habib, A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad112 · Cited by 48
Ezeh, U. I., Pisarska, M. D., & Azziz, R. (2022) · Human Reproduction · doi:10.1093/humrep/deac001 · Cited by 40
Self-citationNonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
Doycheva, I., & Ehrmann, D. A. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.020 · Cited by 40
Kim, C., Catov, J. M., Schreiner, P. J., Appiah, D., Wellons, M., Siscovick, D. S., Calderon‐Margalit, R., Huddleston, H. G., Ebong, I., & Lewis, C. E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028132 · Cited by 39
Zahid, S., Khan, M. Z., Gowda, S. N., Faza, N. N., Honigberg, M. C., Vaught, A. “. J., Guan, C. S., Minhas, A., & Michos, E. D. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025839 · Cited by 33
Rempert, A. N., Sarria, I., Standeven, L. R., Nylander, E., Segars, J., & Singh, B. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01285-x · Cited by 25
Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome
Joham, A. E., Tay, C. T., Laven, J. S. E., Louwers, Y. V., & Azziz, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae910 · Cited by 36
Self-citationNisa, K. U., Tarfeen, N., Mir, S. A., Waza, A. A., Ahmad, M. B., & Ganai, B. A. (2023) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01130-7 · Cited by 30
“Assessing the economical burden of this disease (initial diagnosis and treatment of menstrual dysfunction, infertility, and hirsutism) it estimates approximately $3.7 billion annually in 2020 USD [34].”
InfluentialTalebi, S., Zeraattalab-Motlagh, S., Payandeh, N., Jalilpiran, Y., Ansari, S., Mohammadi, H., Djafarian, K., Ranjbar, M., Sadeghi, S., Taghizadeh, M., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1178842 · Cited by 30
“7 million per year in the United States and taking into account the cost of pregnancy-related and long-term complications, it has risen to $8 million per year (10).”
BackgroundPossible cognition changes in women with polycystic ovary syndrome: a narrative review
Naz, M. S. G., Rahnemaei, F. A., Tehrani, F. R., Sayehmiri, F., Ghasemi, V., Banaei, M., & Ozgoli, G. (2023) · Obstetrics & Gynecology Science · doi:10.5468/ogs.22165 · Cited by 28
Barberis, N., Calaresi, D., Cannavò, M., & Verrastro, V. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2023.152373 · Cited by 29
Berni, T. R., Morgan, C. L., & Rees, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae518 · Cited by 25
“The group extended these analyses to estimate annual costs of PCOS-associated type 2 diabetes and stroke as $1.5 and $2.4 billion in 2020 US dollars, respectively ( 8).”
BackgroundInfluentialChanges in the global burden of polycystic ovary syndrome from 1990 to 2021
Lin, T., Xie, B., Yang, J., Xu, J., & Chen, F. (2025) · Reproductive Health · doi:10.1186/s12978-025-02016-y · Cited by 37
“PCOS affects 8–13% of women [1], resulting in over $8 billion in annual healthcare expenditures within the United States [25].”
Barberis, N., Calaresi, D., Cannavò, M., & Verrastro, V. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.962083 · Cited by 23
Sukhapure, M., Eggleston, K., Fenton, A. J., FRAMPTON, C. M. A., Porter, R., & Douglas, K. M. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s385014 · Cited by 19
“Worldwide prevalence rates are between 5% and 10% depending on the diagnostic definition used,(2) and the economic impact is high, with a recent meta-analysis estimating the annual economic healthcare burden of PCOS was $8 billion in the United States.(3) It is a heterogenous disorder defined by a combination of signs…”
BackgroundKhatun, M., Lundin, K., Naillat, F., Loog, L., Saarela, U., Tuuri, T., Salumets, A., Piltonen, T., & Tapanainen, J. S. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10627-w · Cited by 23
Palomba, S., Seminara, G., Costanzi, F., Caserta, D., & Aversa, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122859 · Cited by 21
Parker, J., O'Brien, C. L., Yeoh, C., Gersh, F. L., & Brennecke, S. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061774 · Cited by 23
Associations of Childhood Adiposity and Cardiometabolic Biomarkers With Adolescent PCOS
Whooten, R., Rifas‐Shiman, S. L., Perng, W., Chavarro, J. E., Taveras, E. M., Oken, E., & Hivert, M. (2024) · PEDIATRICS · doi:10.1542/peds.2023-064894 · Cited by 20
Shi, M., Li, X., Xing, L., Li, Z., Zhou, S., Wang, Z., Zou, X., She, Y., Zhao, R., & Qin, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121556 · Cited by 26
Silva, E. L., Lane, K., Cheng, J. J., Popp, Z., van Loenen, B. D., Coull, B. A., Hart, J. E., James-Todd, T. M., & Mahalingaiah, S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae705 · Cited by 26
“In 2022, BMC was ranked the number 1 most socially responsible hospital in Massachusetts and the number 1 most racially inclusive hospital in the United States by the Lown Institute (61, 62).”
InfluentialRío, J. P. D., Tsompanidis, A., Gaspar, P. A., Maturana, A., Rojas, G., Dagnino‐Subiabre, A., Olea, A., Maliqueo, M. A., Echiburú, B., de Guevara, A. L., et al. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101188 · Cited by 15
Abu‐Zaid, A., Baradwan, S., Bukhari, I. A., Alyousef, A., Abuzaid, M., Saleh, S. A. K., Adly, H. M., Alomar, O., & Al-Badawi, I. A. (2023) · Obstetrics & Gynecology Science · doi:10.5468/ogs.23206 · Cited by 21
“PCOS accounts for 50-70% of all infertility cases in women of childbearing age who are not ovulating [1-3] and affects approximately 10% of women of reproductive age world-wide, with annual medical expenses >$4 billion in the United States alone [4,5].”
Badenhorst, C. E. (2024) · Sports Medicine · doi:10.1007/s40279-024-02061-w · Cited by 14
Wright, P. J., Corbett, C. F., Pinto, B. M., Dawson, R. M., & Wirth, M. D. (2021) · Women s Health · doi:10.1177/17455065211065865 · Cited by 19
Kiconco, S., Tay, C. T., Rassie, K. L., Azziz, R., Teede, H. J., & Joham, A. E. (2022) · Human Reproduction · doi:10.1093/humrep/deac077 · Cited by 14
“…is associated with a substantial economic burden, conservatively estimated to exceed an annual total cost of $8 billion USD in the USA alone (2020 USD), including healthcare costs related to diagnosis, reproductive, metabolic, vascular and pregnancy-related morbidities (Riestenberg et al. , 2022).”
Self-citationMyerson, M. L., Paparodis, R. D., Block, R., Karalis, D. G., Mintz, G. L., Brinton, E. A., & Wild, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.131 · Cited by 19
Liu, Y., Guo, Y., Yan, X., Ding, R., Tan, H., Wang, Y., Wang, X., & Wang, L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071051 · Cited by 14
Environmental Exposures and Polycystic Ovary Syndrome: A Review
Peebles, E., & Mahalingaiah, S. (2024) · Seminars in Reproductive Medicine · doi:10.1055/s-0044-1801405 · Cited by 18
“15 21”
PCOS and the risk of pre-eclampsia
Joshi, A., Aluko, A., Styer, A. K., Young, B. C., Johnson, K. M., Hacker, M. R., & Modest, A. M. (2022) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2022.05.026 · Cited by 15
Guo, Y., Liu, Y., Yan, X., Ding, R., & Wang, L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.918991 · Cited by 15
“A recent study (Carrie et al., 2021) reported that PCOS increases the financial burden of patients; if combined with reproductive endocrine diseases (menstrual dysfunction/abnormal uterine bleeding, hirsutism, and infertility), the total economic burden of PCOS was approximately US $8 billion per year in 2020.”
BackgroundPanchpuri, M., Kisku, A., Painuli, R., Pant, G., & Kumar, C. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02117-5 · Cited by 13
Peven, K., Wickham, A. P., Wilks, O., Kaplan, Y. C., Marhol, A., Ahmed, S., Bamford, R., Cunningham, A. C., Prentice, C., Meczner, A., et al. (2023) · JMIR mHealth and uHealth · doi:10.2196/46718 · Cited by 9
“Similarly, the economic costs of PCOS on individuals and health care systems are estimated to be US $8 billion per year [8].”
BackgroundAlkhezi, F., AlNemash, N., AlMutairi, J., Saleh, S., Almutairi, M. K., Saleh, S., & Akhtar, S. (2024) · Women s Health Reports · doi:10.1089/whr.2023.0176 · Cited by 17
Wu, X., Wilke, M., Batara, J., Proctor, S. D., Cree‐Green, M., Ghosh, M., Raggi, P., Windram, J. D., Becher, H. H., & Vine, D. F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1520922 · Cited by 10
Chai, O., Feng, X., Tang, N., Cui, D., Li, H., Tian, W., Fan, J., Wang, Y., & Hou, Z. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03976-w · Cited by 14
Palomba, S., Costanzi, F., Cannarella, R., Votino, R., Calogero, A. E., Signore, F., & Caserta, D. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.04.026 · Cited by 9
Nandi, A., Singh, K. D., & Sharma, K. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07187-w · Cited by 13
“The economic burden of PCOS is estimated to be USD 8 billion annually in 2020 [5].”
Habiburrahman, M., Wardoyo, M. P., Putra, A. B., Surya, I. U., & Pratama, G. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100490 · Cited by 7
Zhang, X., Huangfu, Z., & Wang, S. (2023) · Endocrine · doi:10.1007/s12020-023-03467-8 · Cited by 8
“In addition, the economic burden of PCOS has been conservatively estimated to reach $8 billion in 2020 in the United States alone [3].”
BackgroundVasudevan, S., Gautam, R., Maan, P., Arora, A., Ganie, M. A., Jabbar, P. K., & Arora, T. K. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1627670 · Cited by 14
Zhang, C., Lin, Z., Lin, Y., & Ma, H. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01837-6 · Cited by 9
The interplay between migraine, endometriosis and polycystic ovarian syndrome: A systematic review
Gómez‐Dabó, L., Jordà-Baleri, T., Losa-Puig, H., Caronna, E., & Pozo‐Rosich, P. (2025) · Cephalalgia · doi:10.1177/03331024251386776 · Cited by 10
“All together, these conditions signi fi cantly reduce quality of life, contribute to greater disability (4 – 6), and impose a substantial economic burden on healthcare systems (6 – 9).”
Zhou, X., Ma, Q., Yan, Z., Wang, Y., Qin, J., Tong, T., Liang, R., Li, Y., Wang, Y., & Chen, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116517 · Cited by 9
Machado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., Schuh, O., Kaldas, M., Arcaroli, E., Ortiz, J. P., et al. (2024) · Cureus · doi:10.7759/cureus.66691 · Cited by 19
“In the United States, the economic burden of PCOS was estimated at $8 billion annually in 2020, when considering pregnancy-related and long-term morbidities [3].”
BackgroundPalomba, S., Molinaro, M., Ingargiola, A., & Aversa, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418985 · Cited by 8
Wu, T., Xu, G., Hong, X., Fan, H., Zeng, J., Liu, Y., Hu, J., Liang, F., Yang, J., & Chen, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1509152 · Cited by 9
Jin, B., Zhang, Y., Zhang, Z., Yang, G., Pan, Y., Xie, L., Liu, J., & Shen, W. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8698755 · Cited by 7
“alone, the cost of diagnosing, treating, and caring for patients with PCOS was estimated to be $8 billion yearly in 2020, which places an immense financial burden on both the patient’s family and society as a whole [5].”
BackgroundDemis, A., Kiconco, S., Earnest, A., Khomami, M. B., Dhungana, R. R., Azziz, R., Сутурина, Л. В., Zhao, X., Gambineri, A., Tehrani, F. R., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04221-9 · Cited by 10
Self-citationNaming in medicine: how disease nomenclature shapes diagnosis, research and patient lives
Teede, H. J., Morman, R., Dokras, A., Khomami, M. B., Piltonen, T., Norman, R. J., & Stener‐Victorin, E. (2026) · Nature Medicine · doi:10.1038/s41591-026-04456-w · Cited by 6
Berkel, Ç. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13933 · Cited by 6
Reich, L. A., Fleur, R. G. S., Gjelsvik, A., Field, A. E., & Ziobrowski, H. N. (2025) · Human Reproduction · doi:10.1093/humrep/deae294 · Cited by 6
Zhou, Z., Zhang, Y., Tan, C., Zhang, J., Yi, G., Wang, B., Li, Y., Lu, H., Lu, W., & Zhang, X. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02632-5 · Cited by 6
Common Beverage Consumption and Benign Gynecological Conditions
Michel, R., Hazimeh, D., Saad, E., Olson, S. L., Musselman, K., Elgindy, E. A., & Borahay, M. A. (2024) · Beverages · doi:10.3390/beverages10020033 · Cited by 11
“[101,102].”
BackgroundPCOS and Mendelian Randomization: Too Soon?
Azziz, R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab827 · Cited by 7
Self-citationZeng, W., Gan, D., Ou, J., & Tomlinson, B. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1642369 · Cited by 9
Yang, H., Xiao, Y.-Q., Liu, J., Xu, G., Li, J., Xiao, Z.-Y., Zhou, J., Zheng, X., Liu, L.-Y., Yu, Z., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059090 · Cited by 7
Peebles, E., Wang, Z., Dracup, E., Sarcione, C., Curry, C. L., Abrams, K., Onnela, J.-P. “., Williams, M. A., Hauser, R. B., Coull, B. A., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1585628 · Cited by 5
Uptake of the core outcome set on polycystic ovary syndrome before and after its publication
Li, W., Li, G., Chi, H., Wang, H., & Zeng, L. (2023) · Human Reproduction · doi:10.1093/humrep/dead149 · Cited by 6
“Furthermore, taking into consideration the aforementioned outcomes, it was proved to result in a significant increase in healthcare-related economic burdens (Riestenberg et al. , 2022).”
Polycystic ovary syndrome v.2023: Simplified diagnostic criteria for an East Asian phenotype
Yong, E., Teoh, W. S., & Huang, Z. (2023) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202369 · Cited by 7
Carriero, V. C., Forte, G., Dinicola, S., Oliva, M. M., Mudarris, G. A., & Unfer, V. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.113947 · Cited by 6
The impact of sleeve gastrectomy on polycystic ovarian syndrome: a single-center 1-year cohort study
Alamdari, N. M., Sadegh, G. H. M., Farsi, Y., Besharat, S., Hajimirzaie, S. H., & Abbasi, M. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03488-2 · Cited by 7
Li, J., Zhong, Y., Wang, X., Lin, L.-Z., Tang, Y., Liang, S., Chen, W., Liufu, L.-L., Li, Q., & Zhong, X. (2025) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2025.105051 · Cited by 9
Liu, J., Cai, Y., Li, J., & Zhang, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329090 · Cited by 8
Magnusson, B. M., Long, M. C., Larson, R. J., Maycock, L., Wood, E. H., Stratford, G., & Thacker, E. L. (2025) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2025.2541951 · Cited by 5
“In 2022, Riestenberg et al. estimated the economic burden of PCOS, including direct and indirect costs, such as pregnancy-related complications and long-term morbidities at over $8 billion USD in 2020 [6].”
The Economic Cost of Obesity: A Cost-of-Illness Study in Greece
Papantoniou, P., & Maniadakis, N. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-025-01002-6 · Cited by 6
Chaker, W. M.-M., Adi, R. M., Madkour, M. I., Farhat, N. M., Abdelrahim, D. N., Saber-Ayad, M. M., Muhammad, J. S., Mohammed, G., Mousa, N. A., Saadi, A., et al. (2025) · Journal of Nutrition and Metabolism · doi:10.1155/jnme/8817919 · Cited by 4
“Our data also suggest that PCOS may be more prevalent in high-income individuals, as they may have better access to healthcare services and may, therefore, be more likely to be diagnosed with PCOS [25].”
Guo, Y., Chen, H., Zha, L., Bai, D., & Jin, L. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.06.032 · Cited by 5
Is polycystic ovary syndrome undervalued in China?
Zheng, X., & Wang, C. C. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100513 · Cited by 4
Metadata
- Authors
- Riestenberg, C., Jagasia, A., Markovic, D., Buyalos, R. P., & Azziz, R.
- Affiliations
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Corresponding author
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-09-21
- Volume
- 107
- Issue
- 2
- Pages
- 575-585
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3199422888
- Cited by
- 210
- References
- 36
- Citations by year
- 2026: 58 · 2025: 56 · 2024: 35 · 2023: 37 · 2022: 21 · 2021: 3
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Research and Education Excellence
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, pregnancy complications, long-term health effects
- MeSH terms
- Health Expenditures, Female, Humans, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, United States, Comorbidity, Prevalence, Case-Control Studies, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.